A detailed history of Ci Investments Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Ci Investments Inc. holds 3,069 shares of TGTX stock, worth $98,821. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,069
Previous 3,046 0.76%
Holding current value
$98,821
Previous $54,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$17.21 - $25.28 $395 - $581
23 Added 0.76%
3,069 $72,000
Q2 2024

Aug 12, 2024

SELL
$13.32 - $19.19 $3,036 - $4,375
-228 Reduced 6.96%
3,046 $54,000
Q1 2024

May 13, 2024

BUY
$13.02 - $21.3 $39 - $63
3 Added 0.09%
3,274 $50,000
Q4 2023

Feb 12, 2024

BUY
$6.68 - $18.81 $7,581 - $21,349
1,135 Added 53.14%
3,271 $56,000
Q3 2023

Nov 13, 2023

SELL
$8.36 - $26.5 $535 - $1,696
-64 Reduced 2.91%
2,136 $18,000
Q2 2023

Aug 11, 2023

SELL
$15.48 - $35.0 $105,171 - $237,790
-6,794 Reduced 75.54%
2,200 $55,000
Q1 2023

May 12, 2023

SELL
$10.23 - $19.34 $1,186 - $2,243
-116 Reduced 1.27%
8,994 $135,000
Q4 2022

Feb 10, 2023

BUY
$5.01 - $11.83 $33,867 - $79,970
6,760 Added 287.66%
9,110 $108,000
Q3 2022

Nov 14, 2022

SELL
$4.57 - $8.4 $799 - $1,470
-175 Reduced 6.93%
2,350 $14,000
Q2 2022

Aug 12, 2022

BUY
$3.74 - $10.66 $5,621 - $16,021
1,503 Added 147.06%
2,525 $11,000
Q1 2022

May 12, 2022

BUY
$7.81 - $20.45 $7,981 - $20,899
1,022 New
1,022 $10,000
Q4 2021

Feb 11, 2022

SELL
$15.2 - $35.51 $106 - $248
-7 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$21.78 - $40.45 $152 - $283
7 New
7 $0

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.68B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Ci Investments Inc. Portfolio

Follow Ci Investments Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ci Investments Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ci Investments Inc. with notifications on news.